April 28, 2022
Article
Cabotegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration.
March 23, 2022
The FDA recently approved cabotegravir 200 mg/mL and rilpivirine 300 mg/mL as a once-monthly treatment for adults with HIV-1 who are virologically suppressed on a stable antiretroviral regimen.